Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial Post published:January 11, 2022 Post category:Press Release
Psychedelic Research and Clinical Trials in 2021 Post published:January 10, 2022 Post category:Analysis
Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds Post published:January 10, 2022 Post category:Press Release
Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank Post published:January 10, 2022 Post category:Press Release
Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services Post published:January 7, 2022 Post category:Press Release
Stephen Hurst Resigns from MindMed Board of Directors Post published:January 7, 2022 Post category:Press Release
Psychedelic Bulletin: Big Pharma’s Foray Into Psychedelics; Psilocybin Trial Makes Headlines; Bill to Legalize Psilocybin in Washington State Filed Post published:January 7, 2022 Post category:Psychedelic Bulletin
Cybin Announces Additional Adelia Milestone Achievement Post published:January 6, 2022 Post category:Press Release
Levitee Labs Announces Medical Advisory Board Post published:January 6, 2022 Post category:Press Release
Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete Second Evaluation Under a Health Canada Approved cGMP Laboratory Post published:January 6, 2022 Post category:Press Release